Drug Patents owned by Arbor Pharms Llc
1. Drug name - CETYLEV
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9561204 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(9 years from now) | |
| US8747894 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(9 years from now) | |
| US9427421 | ARBOR PHARMS LLC | Effervescent compositions containing N-acetylcysteine |
May, 2032
(9 years from now) | |
Drugs and Companies using ACETYLCYSTEINE ingredient
Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions
Dosage: TABLET, EFFERVESCENT;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5GM | TABLET, EFFERVESCENT;ORAL | Discontinued |
| 500MG | TABLET, EFFERVESCENT;ORAL | Discontinued |
2. Drug name - EDARBI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7157584 | ARBOR PHARMS LLC | Benzimidazole derivative and use thereof |
May, 2025
(2 years from now) | |
| CN101381366A | ARBOR PHARMS LLC | Benzimidazole Derivative And Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| CN101381366B | ARBOR PHARMS LLC | Benzimidazole Derivatives And Their Pharmaceutical Use |
Feb, 2025
(2 years from now) | |
| CN1946717A | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use |
Feb, 2025
(2 years from now) | |
| CN100503605C | ARBOR PHARMS LLC | Benzimidazole Derivatives And Their Use As A Ii Receptor Antagonists |
Feb, 2025
(2 years from now) | |
| IN242537B | ARBOR PHARMS LLC | Benzimidazole Derivative And A Process For The Preparation Thereof |
Feb, 2025
(2 years from now) | |
| IN200602785P2 | ARBOR PHARMS LLC | Benzimidazole Derivative And Use Thereof |
Feb, 2025
(2 years from now) | |
| EP2119715A1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP2119715B1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1857457A3 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1857457B1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1857457A2 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1718641A2 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist |
Dec, 2026
(4 years from now) | |
| EP1718641B1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist |
Dec, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | ARBOR PHARMS LLC | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(2 years from now) | |
| US9066936 | ARBOR PHARMS LLC | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(5 years from now) | |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG MEDOXOMIL | TABLET;ORAL | Prescription |
| EQ 80MG MEDOXOMIL | TABLET;ORAL | Prescription |
3. Drug name - EDARBYCLOR
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7157584 | ARBOR PHARMS LLC | Benzimidazole derivative and use thereof |
May, 2025
(2 years from now) | |
| CN101381366A | ARBOR PHARMS LLC | Benzimidazole Derivative And Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| CN101381366B | ARBOR PHARMS LLC | Benzimidazole Derivatives And Their Pharmaceutical Use |
Feb, 2025
(2 years from now) | |
| CN1946717A | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use |
Feb, 2025
(2 years from now) | |
| CN100503605C | ARBOR PHARMS LLC | Benzimidazole Derivatives And Their Use As A Ii Receptor Antagonists |
Feb, 2025
(2 years from now) | |
| IN242537B | ARBOR PHARMS LLC | Benzimidazole Derivative And A Process For The Preparation Thereof |
Feb, 2025
(2 years from now) | |
| IN200602785P2 | ARBOR PHARMS LLC | Benzimidazole Derivative And Use Thereof |
Feb, 2025
(2 years from now) | |
| EP2119715A1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP2119715B1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1857457A3 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1857457B1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1857457A2 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As Aii Receptor Antagonist |
Feb, 2025
(2 years from now) | |
| EP1718641A2 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist |
Dec, 2026
(4 years from now) | |
| EP1718641B1 | ARBOR PHARMS LLC | Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist |
Dec, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7572920 | ARBOR PHARMS LLC | Benzimidazole derivative and use as a II receptor antagonist |
Jan, 2025
(2 years from now) | |
| US9066936 | ARBOR PHARMS LLC | Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent |
Mar, 2028
(5 years from now) | |
| US9169238 | ARBOR PHARMS LLC | Solid pharmaceutical composition |
Feb, 2030
(7 years from now) | |
| US9387249 | ARBOR PHARMS LLC | Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone |
Jul, 2031
(8 years from now) | |
Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient
Treatment: Treatment of hypertension
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG MEDOXOMIL;12.5MG | TABLET;ORAL | Prescription |
| EQ 40MG MEDOXOMIL;25MG | TABLET;ORAL | Prescription |
4. Drug name - EVEKEO ODT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10130580 | ARBOR PHARMS LLC | Taste-masked pharmaceutical compositions |
Apr, 2024
(1 year, 6 months from now) | |
| US11160772 | ARBOR PHARMS LLC | Oral amphetamine composition |
Mar, 2037
(14 years from now) | |
| US10441554 | ARBOR PHARMS LLC | Oral amphetamine composition |
Mar, 2037
(14 years from now) | |
Drugs and Companies using AMPHETAMINE SULFATE ingredient
Treatment: NA
Dosage: TABLET, ORALLY DISINTEGRATING;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 2.5MG | TABLET, ORALLY DISINTEGRATING;ORAL | Discontinued |
| 5MG | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
| 10MG | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
| 15MG | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
| 20MG | TABLET, ORALLY DISINTEGRATING;ORAL | Prescription |
5. Drug name - HORIZANT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8048917 | ARBOR PHARMS LLC | Prodrugs of GABA analogs, compositions and uses thereof |
Nov, 2022
(a month from now) | |
| US6818787 | ARBOR PHARMS LLC | Prodrugs of GABA analogs, compositions and uses thereof |
Apr, 2025
(2 years from now) | |
| US8026279 | ARBOR PHARMS LLC | Crystalline form of γ-aminobutyric acid analog |
Nov, 2026
(4 years from now) | |
| CN1533270A | ARBOR PHARMS LLC | Oral Administration Formulation Has Reduced Toxicity Of Prodrugs Of Gaba Analogues |
Dec, 2011
(10 years ago) | |
| CN1675165A | ARBOR PHARMS LLC | Method For Synthesis Of Gaba Analogues Acyloxy Alkyl Derivative |
Aug, 2014
(8 years ago) | |
| CN100540526C | ARBOR PHARMS LLC | Method For The Synthesis Of Gaba Analogue Acyloxy Alkyl Derivative |
Aug, 2014
(8 years ago) | |
| CN101381339B | ARBOR PHARMS LLC | Gaba Analog Prodrug, And Application Of The Composition |
Aug, 2016
(6 years ago) | |
| CN101381339A | ARBOR PHARMS LLC | Prodrugs Of Gaba Analogues, And Uses Of Compositions Thereof |
Aug, 2016
(6 years ago) | |
| CN1867322A | ARBOR PHARMS LLC | Crystalline Form Of -Aminobutyric Acid Analog |
Dec, 2017
(4 years ago) | |
| CN1867322B | ARBOR PHARMS LLC | Crystalline Form Of Gamma-Aminobutyric Acid Analog |
Dec, 2017
(4 years ago) | |
| CN1753673B | ARBOR PHARMS LLC | Prodrug Of Gaba Analogue, Composition And Application Thereof |
Jul, 2018
(4 years ago) | |
| CN1753673A | ARBOR PHARMS LLC | Prodrugs Of Gaba Analogs, And Compositions And Uses Thereof |
Jul, 2018
(4 years ago) | |
| CN101434572A | ARBOR PHARMS LLC | Prodrug Of Gaba Analogue, Composition And Application Thereof |
Jun, 2022
(3 months ago) | |
| CN101434572B | ARBOR PHARMS LLC | Prodrug Of Gaba Analogue, Composition And Application Thereof |
Jun, 2022
(3 months ago) | |
| IN200600341P3 | ARBOR PHARMS LLC | Crystalline Form Of Gamma-Aminobutyric Acid Analog |
Oct, 2024
(2 years from now) | |
| IN237299B | ARBOR PHARMS LLC | Crystalline Form Of Gama-Aminobutyric Acid Analog |
Oct, 2024
(2 years from now) | |
| EP1404324B1 | ARBOR PHARMS LLC | Prodrugs Of Gaba Analogs, Compositions And Uses Thereof |
Jun, 2022
(3 months ago) | |
| EP1404324A4 | ARBOR PHARMS LLC | Prodrugs Of Gaba Analogs, Compositions And Uses Thereof |
Jun, 2022
(3 months ago) | |
| EP1404324B2 | ARBOR PHARMS LLC | Prodrugs Of Gaba Analogs, Compositions And Uses Thereof |
Jun, 2022
(3 months ago) | |
| EP1404324A2 | ARBOR PHARMS LLC | Prodrugs Of Gaba Analogs, Compositions And Uses Thereof |
Jun, 2022
(3 months ago) | |
| EP1902714B1 | ARBOR PHARMS LLC | Prodrugs Of Gaba Analogs, Compositions And Uses Thereof |
Jun, 2022
(3 months ago) | |
| EP1902714A1 | ARBOR PHARMS LLC | Prodrugs Of Gaba Analogs, Compositions And Uses Thereof |
Jun, 2022
(3 months ago) | |
| EP2275401A1 | ARBOR PHARMS LLC | Crystalline 1-{[(Alpha-Isobutanoyloxyethoxy)Carbonyl]Aminomethyl}-1-Cyclohexane Acetic Acid |
Jun, 2023
(8 months from now) | |
| EP2275401B1 | ARBOR PHARMS LLC | Crystalline 1-{[(Alpha-Isobutanoyloxyethoxy)Carbonyl]Aminomethyl}-1-Cyclohexane Acetic Acid |
Jun, 2023
(8 months from now) | |
| EP1677767A4 | ARBOR PHARMS LLC | Crystalline Form Of Gamma-Aminobutyric Acid Analog |
Oct, 2024
(2 years from now) | |
| EP1677767B1 | ARBOR PHARMS LLC | Crystalline Form Of Gamma-Aminobutyric Acid Analog |
Oct, 2024
(2 years from now) | |
| EP1677767A2 | ARBOR PHARMS LLC | Crystalline Form Of Gamma-Aminobutyric Acid Analog |
Oct, 2024
(2 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8686034 | ARBOR PHARMS LLC | Crystalline form of γ-aminobutyric acid analog |
Jan, 2025
(2 years from now) | |
| US8114909 | ARBOR PHARMS LLC | Treating or preventing restless legs syndrome using prodrugs of GABA analogs |
Apr, 2026
(3 years from now) | |
| US8795725 | ARBOR PHARMS LLC | GABA analog prodrug sustained release oral dosage forms |
Jun, 2029
(6 years from now) | |
Drugs and Companies using GABAPENTIN ENACARBIL ingredient
Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; management of postherpetic neuralgia (phn) in adults; Treatment of moderate-to-severe primary restless leg syndrome in adults
Dosage: TABLET, EXTENDED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 300MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
| 600MG | TABLET, EXTENDED RELEASE;ORAL | Prescription |
6. Drug name - NYMALIZE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7070581 | ARBOR PHARMS LLC | Dispenser for medicaments and method and apparatus for making same |
Jun, 2023
(8 months from now) | |
| US8517997 | ARBOR PHARMS LLC | Dispenser for medicaments and method and apparatus for making same |
May, 2024
(1 year, 7 months from now) | |
| US11207306 | ARBOR PHARMS LLC | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(15 years from now) | |
| US10576070 | ARBOR PHARMS LLC | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(15 years from now) | |
| US10342787 | ARBOR PHARMS LLC | Non-aqueous liquid nimodipine compositions |
Apr, 2038
(15 years from now) | |
Drugs and Companies using NIMODIPINE ingredient
Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 3MG/ML | SOLUTION;ORAL | Discontinued |
| 6MG/ML | SOLUTION;ORAL | Prescription |
7. Drug name - SOTYLIZE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10206895 | ARBOR PHARMS LLC | Sotalol compositions and uses of the same |
Apr, 2034
(11 years from now) | |
| US11013703 | ARBOR PHARMS LLC | Sotalol compositions and uses of the same |
Apr, 2034
(11 years from now) | |
| US9724297 | ARBOR PHARMS LLC | Sotalol compositions and uses of the same |
Aug, 2035
(12 years from now) | |
Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient
Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening; Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG/ML (5MG/ML) | SOLUTION;ORAL | Prescription |
8. Drug name - TRIPTODUR KIT
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10166181 | ARBOR PHARMS LLC | Slow release pharmaceutical composition made of microgranules |
Jun, 2029
(6 years from now) | |
Drugs and Companies using TRIPTORELIN PAMOATE ingredient
Treatment: NA
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
| Strength | Dosage | Availability |
|---|---|---|
| EQ 22.5MG BASE/VIAL | FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.